The higher intertumoral expression of TIM-3 in GBM in comparison to low-grade gliomas in CD4+ and CD8+ T cells is indicative of the contribution of TIM-3 to glioma severity in patients [100]. The gene discussed is CD8A; the disease is central nervous system cancer.